These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16830701)

  • 1. Resolving the paradigm crisis in intravenous iron and erythropoietin management.
    Besarab A
    Kidney Int Suppl; 2006 May; (101):S13-8. PubMed ID: 16830701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenging the boundaries of anemia management: a balanced approach to i.v. iron and EPO therapy.
    Coyne D
    Kidney Int Suppl; 2006 May; (101):S1-3. PubMed ID: 16830698
    [No Abstract]   [Full Text] [Related]  

  • 3. Overcoming barriers that inhibit proper treatment of anemia.
    Agarwal R
    Kidney Int Suppl; 2006 May; (101):S9-12. PubMed ID: 16830700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
    Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
    Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Fishbane S; Frei GL; Maesaka J
    Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving target hematocrit in dialysis patients: new concepts in iron management.
    Nissenson AR
    Am J Kidney Dis; 1997 Dec; 30(6):907-11. PubMed ID: 9398140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 10. Implementing continuous quality improvement strategies for improving iron replacement in hemodialysis patients.
    Trenkle JA
    Nephrol Nurs J; 2001 Oct; 28(5):561-5. PubMed ID: 12143432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines.
    Fishbane S
    Semin Dial; 2008; 21(3):217-20. PubMed ID: 18248518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
    Park L; Uhthoff T; Tierney M; Nadler S
    Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristic of parenteral iron supplementation in hemodialysis patients receiving erythropoietin therapy.
    Kao HH; Chen KS; Tsai CJ; Lee CC; Chang HY
    Chang Gung Med J; 2000 Oct; 23(10):608-13. PubMed ID: 11126152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron indices: what do they really mean?
    Coyne D
    Kidney Int Suppl; 2006 May; (101):S4-8. PubMed ID: 16830699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous iron supplementation in end-stage renal disease patients.
    Matzke GR
    Am J Kidney Dis; 1999 Mar; 33(3):595-7. PubMed ID: 10070926
    [No Abstract]   [Full Text] [Related]  

  • 16. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous low-dose iron administration in hemodialysis patients treated with erythropoietin: 1-year follow-up study.
    Kurihara I; Soma J; Nakayama K; Sato H; Saito T
    Nephron; 2000 Oct; 86(2):200-1. PubMed ID: 11014998
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients.
    Navarro JF; Teruel JL; Liaño F; Marcén R; Ortuño J
    Am J Nephrol; 1996; 16(4):268-72. PubMed ID: 8739277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
    Fernández-Gallego J; Martín MA; Alonso A; Toledo R
    Nefrologia; 2006; 26(1):143-4. PubMed ID: 16649439
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.